Achieving the "Ending the HIV Epidemic in the U.S." incidence reduction goals among at-risk populations in the South.

Deven T Hamilton, Karen W Hoover, Dawn K Smith, Kevin P Delaney, Li Yan Wang, Jingjing Li, Tamika Hoyte, Samuel M Jenness, Steven M Goodreau
Author Information
  1. Deven T Hamilton: Center for Studies in Demography and Ecology, University of Washington, 206 Raitt Hall, UW, Box 353412, Seattle, WA, 98195-3412, USA. dth2@uw.edu. ORCID
  2. Karen W Hoover: Division of HIV Prevention (DHP), National Center for HIV, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA.
  3. Dawn K Smith: Division of HIV Prevention (DHP), National Center for HIV, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA.
  4. Kevin P Delaney: Division of HIV Prevention (DHP), National Center for HIV, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA.
  5. Li Yan Wang: Division of Adolescent and School Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  6. Jingjing Li: Division of Adolescent and School Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  7. Tamika Hoyte: National Center for HIV, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA.
  8. Samuel M Jenness: Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
  9. Steven M Goodreau: Center for Studies in Demography and Ecology, University of Washington, 206 Raitt Hall, UW, Box 353412, Seattle, WA, 98195-3412, USA.

Abstract

INTRODUCTION: Antiretroviral medication coverage remains sub-optimal in much of the United States, particularly the Sothern region, and Non-Hispanic Black or African American persons (NHB) continue to be disproportionately impacted by the HIV epidemic. The "Ending the HIV Epidemic in the U.S." (EHE) initiative seeks to reduce HIV incidence nationally by focusing resources towards the most highly impacted localities and populations. This study evaluates the impact of hypothetical improvements in ART and PrEP coverage to estimate the levels of coverage needed to achieve EHE goals in the South.
METHODS: We developed a stochastic, agent-based network model of 500,000 individuals to simulate the HIV epidemic and hypothetical improvements in ART and PrEP coverage.
RESULTS: New infections declined by 78.6% at 90%/40% ART/PrEP and 94.3% at 100%/50% ART/PrEP. Declines in annual incidence rates surpassed 75% by 2025 with 90%/40% ART/PrEP and 90% by 2030 with 100%/50% ART/PrEP coverage. Increased ART coverage among NHB MSM was associated with a linear decline in incidence among all MSM. Declines in incidence among Hispanic/Latino and White/Other MSM were similar regardless of which MSM race group increased their ART coverage, while the benefit to NHB MSM was greatest when their own ART coverage increased. The incidence rate among NHB women declined by over a third when either NHB heterosexual men or NHB MSM increased their ART use respectively. Increased use of PrEP was associated with a decline in incidence for the groups using PrEP. MSM experienced the largest absolute declines in incidence with increasing PrEP coverage, followed by NHB women.
CONCLUSIONS: Our analysis indicates that it is possible to reach EHE goals. The largest reductions in HIV incidence can be achieved by increasing ART coverage among MSM and all race groups benefit regardless of differences in ART initiation by race. Improving ART coverage to���>���90% should be prioritized with a particular emphasis on reaching NHB MSM. Such a focus will reduce the largest number of incident cases, reduce racial HIV incidence disparities among both MSM and women, and reduce racial health disparities among persons with HIV. NHB women should also be prioritized for PrEP outreach.

Keywords

References

  1. J Infect Dis. 2021 Jan 4;223(1):72-82 [PMID: 32882043]
  2. J Acquir Immune Defic Syndr. 2021 May 1;87(1):639-643 [PMID: 33512848]
  3. Clin Infect Dis. 2021 Oct 5;73(7):1149-1156 [PMID: 33864370]
  4. JMIR Public Health Surveill. 2016 Apr 21;2(1):e14 [PMID: 27227149]
  5. J Acquir Immune Defic Syndr. 2020 Aug 15;84(5):443-452 [PMID: 32692102]
  6. Lancet. 2021 Mar 20;397(10279):1107-1115 [PMID: 33617768]
  7. J Adolesc Health. 2021 Mar;68(3):488-496 [PMID: 32798099]
  8. J Acquir Immune Defic Syndr. 2021 May 1;87(1):644-651 [PMID: 33443963]
  9. AIDS. 2020 Nov 15;34(14):2103-2113 [PMID: 32910062]
  10. J Infect Dis. 2010 May 15;201(10):1488-97 [PMID: 20384495]
  11. Sex Transm Dis. 2021 May 1;48(5):e59-e63 [PMID: 33534405]
  12. JAMA. 2019 Mar 5;321(9):844-845 [PMID: 30730529]
  13. J Stat Softw. 2008;24(1):1548-7660 [PMID: 18618019]
  14. Ann Epidemiol. 2018 Dec;28(12):841-849 [PMID: 29983236]
  15. J Stat Softw. 2008 May 1;24(3):nihpa54860 [PMID: 19756229]
  16. Am J Epidemiol. 2019 Apr 1;188(4):743-752 [PMID: 30312365]
  17. J Int AIDS Soc. 2021 Oct;24(10):e25826 [PMID: 34605174]
  18. J Comput Graph Stat. 2015;24(2):502-519 [PMID: 26321857]
  19. Ann Intern Med. 2021 Nov;174(11):1542-1553 [PMID: 34543589]
  20. Lancet. 2021 Mar 20;397(10279):1095-1106 [PMID: 33617774]
  21. JAMA Intern Med. 2020 Jan 1;180(1):117-125 [PMID: 31738378]
  22. J Stat Softw. 2018 Apr;84: [PMID: 29731699]
  23. J Acquir Immune Defic Syndr. 2015 Dec 1;70(4):444-51 [PMID: 26302431]
  24. Clin Infect Dis. 2013 Oct;57(8):1164-71 [PMID: 23797289]
  25. AIDS Behav. 2022 Nov 22;: [PMID: 36417093]
  26. AIDS Behav. 2021 May;25(5):1361-1365 [PMID: 33599879]
  27. Clin Infect Dis. 2021 Feb 1;72(3):379-385 [PMID: 33527117]
  28. J Acquir Immune Defic Syndr. 2023 Apr 1;92(4):286-292 [PMID: 36484556]
  29. JAMA Intern Med. 2016 Jan;176(1):75-84 [PMID: 26571482]
  30. Epidemics. 2020 Jan 24;30:100386 [PMID: 32004795]
  31. AIDS Behav. 2020 Jul;24(7):2024-2032 [PMID: 32350773]
  32. J Acquir Immune Defic Syndr. 2015 May 1;69 Suppl 1:S8-15 [PMID: 25867782]
  33. Public Health Rep. 2022 Mar-Apr;137(2):310-316 [PMID: 33765400]

Grants

  1. P2C HD042828/NICHD NIH HHS
  2. R01 AI138783/NIAID NIH HHS
  3. R21 MH112449/NIMH NIH HHS

MeSH Term

Female
Humans
Male
Anti-HIV Agents
Goals
HIV Infections
Homosexuality, Male
Incidence
Pre-Exposure Prophylaxis
Sexual and Gender Minorities
United States
Disease Eradication
Health Status Disparities

Chemicals

Anti-HIV Agents

Word Cloud

Created with Highcharts 10.0.0coverageincidenceMSMNHBHIVARTamongPrEPreduceART/PrEPwomenEHEgoalsraceincreasedlargestAntiretroviralpersonsimpactedepidemic"EndingEpidemicUS"populationshypotheticalimprovementsSouthdeclined90%/40%100%/50%DeclinesIncreasedassociateddeclineregardlessbenefitusegroupsincreasingprioritizedracialdisparitiesINTRODUCTION:medicationremainssub-optimalmuchUnitedStatesparticularlySothernregionNon-HispanicBlackAfricanAmericancontinuedisproportionatelyinitiativeseeksnationallyfocusingresourcestowardshighlylocalitiesstudyevaluatesimpactestimatelevelsneededachieveMETHODS:developedstochasticagent-basednetworkmodel500000individualssimulateRESULTS:Newinfections786%943%annualratessurpassed75%202590%2030linearHispanic/LatinoWhite/OthersimilargroupgreatestratethirdeitherheterosexualmenrespectivelyusingexperiencedabsolutedeclinesfollowedCONCLUSIONS:analysisindicatespossiblereachreductionscanachieveddifferencesinitiationImprovingto���>���90%particularemphasisreachingfocuswillnumberincidentcaseshealthalsooutreachAchievingreductionat-risktherapyModelingPre-exposureprophylaxis

Similar Articles

Cited By (6)